Does Crizotinib Auto-Inhibit CYP3A in vivo?

Bland, Abigail R; Shrestha, Nensi; Rosengren, Rhonda J; Ashton, John C

Bland, Abigail R; Shrestha, Nensi; Rosengren, Rhonda J; Ashton, John C.

Afiliação

Bland AR; Department of Pharmacology & Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Shrestha N; Department of Pharmacology & Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Rosengren RJ; Department of Pharmacology & Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Ashton JC; Department of Pharmacology & Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand, john.ashton@otago.ac.nz.

Pharmacology ; 105(11-12): 715-718, 2020.

Article em En | MEDLINE | ID: mdl-32460299

Assuntos

Crizotinibe/farmacologia; Citocromo P-450 CYP3A/metabolismo; Inibidores de Proteínas Quinases/farmacologia; Animais; Masculino; Camundongos; Camundongos Endogâmicos BALB C; Microssomos Hepáticos/enzimologia; Microssomos Hepáticos/metabolismo

Palavras-chave

Anaplastic lymphoma kinase; Cancer; Crizotinib; Cytochrome P450 3A; Pharmacokinetics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Citocromo P-450 CYP3A / Crizotinibe Limite: Animals Idioma: En Revista: Pharmacology Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Nova Zelândia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google